According to the research report titled ‘GLOBAL Neurostimulation Device Market 2019-2027’, available with Market Study Report, global neurostimulation device market is likely to showcase a y-o-y growth rate of 10.23% between 2019 and 2027.
 

Growing elderly population, widespread adoption of MRI scanning equipment, increased pervasiveness of neuro diseases, and supportive reimbursement policies are fueling the growth of neurostimulation device market.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2487390/
 

High costs associated with neuromodulation treatment, easy availability of alternative treatment options, and concerns over side-effect of using the device could potentially hamper the overall industry remuneration.
 

Considering the geographical landscape, global neurostimulation device industry is bifurcated into Middle East & Africa, Latin America, Asia-Pacific, Europe, and North America.
 

According to reliable predictions, Asia-Pacific currently accounts for the largest market share and is likely to witness consistent growth in the subsequent years. Improving healthcare infrastructure, high occurrence of lifestyle-related diseases and increasing popularity of neurostimulation devices among physicians are facilitating the business scenario in Asia-Pacific.
 

The competitive landscape of global neurostimulation device market is defined by companies such as Helius Medical Technologies, Aleva Neurotherapeutics SA, Ekso Bionics Holdings Inc., Boston Scientific Corporation, Ectron Limited, The Magstim Company Limited, Medtronic plc, Dr. Langer Medical GmbH, DePuy Synthes Companies, Cogentix Medical Inc., Cyberonics Inc., Nevro Corp., Hocoma AG, St. Jude Medical Inc., and Neuronetics Inc. among others.